ARVN Stock — Arvinas Inc

Arvinas Inc (ARVN)

Updated October 16, 2026.

ARVN is a Stock. Total return is -56.6% over the past 8.1 years, 252.6 points behind SPY at 196.0%.

Arvinas, Inc. is a clinical-stage biotechnology company developing therapies designed to degrade disease-causing proteins using a technology platform called proteolysis targeting chimeras (PROTACs). The company's pipeline includes candidates in clinical development for neurodegenerative diseases, various cancers, and other conditions, with collaborations including Pfizer, Genentech, Roche, and Bayer. As a pre-revenue clinical-stage biotech company, Arvinas does not currently distribute income and is oriented toward investors seeking long-term capital appreciation rather than current income.

ARVN performance versus SPY

Price and return data through 2026-10-16.

Total return is -56.6% over the past 8.1 years, 252.6 points behind SPY at 196.0%. Over the past year its total return — price change plus distributions reinvested — is -28.0%. Its deepest 1-year drawdown was 50.7%.

ARVN key facts

Asset type

Stock

Asset class

Equity

Inception date

09/27/2018

Distribution frequency

None

Last close

$6.97 (as of 2026-10-16)

Market cap

$449,712,750

Average volume

760770.0

Beta

1.809

Payout ratio

0.0%

P/E ratio

25.81

Forward P/E

17.8571

EPS

$0.27

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ARVN risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 50.7%.

Who may consider ARVN — and who may not

It is a weaker fit for investors who need monthly cash flow (ARVN does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ARVN

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions